Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 3.7%

Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded up 3.7% on Friday . The company traded as high as $12.15 and last traded at $12.15. 4,004 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 80,032 shares. The stock had previously closed at $11.72.

Gyre Therapeutics Stock Up 6.2 %

The stock has a fifty day moving average of $12.53 and a two-hundred day moving average of $16.58.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.04 earnings per share for the quarter. The company had revenue of $27.17 million during the quarter. Equities analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Insider Activity at Gyre Therapeutics

In related news, Director Nassim Usman sold 20,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $14.13, for a total value of $282,600.00. Following the completion of the sale, the director now directly owns 1,636 shares in the company, valued at $23,116.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 2.92% of the stock is currently owned by company insiders.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.